Development of a recombinant protective antigen (rPA) based anthrax vaccine

In Partnering and Corporate strategy, Prophylactic Vaccines by Freya SmaleLeave a Comment

SparVAX

Thomas Fuerst, Executive Vice President, Chief Scientific Officer from PharmAthene joined us at the World Vaccine Congress 2012 in Lyon to give details about the development of a recombinant protective antigen (rPA) based anthrax vaccine. His presentation focused on the following points:

  • Use of modern vaccine production technologies for the manufacture of SparVaxâ„¢
  • Well characterized recombinant Protective Antigen (rPA) anthrax vaccine
  • Established a robust manufacturing platform at full commercial scale
  • Comprehensive set of analytical assays for in process, release, and stability testing

Download the full presentation here >

For more information about this and other topics discussed at the World Vaccine Congress Lyon, subscribe to the Vaccine Nation newsletter, or visit the event website.

For more updates on the vaccines industry, follow us on Twitter: @vaccinenation or join our LinkedIn group: Vaccine Nation

Leave a Comment

Current ye@r *